NASDAQ:SRDX - SurModics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$47.62 -0.83 (-1.71 %)
(As of 01/18/2019 04:00 PM ET)
Previous Close$47.62
Today's Range$47.47 - $48.93
52-Week Range$25.00 - $82.35
Volume49,461 shs
Average Volume100,768 shs
Market Capitalization$653.30 million
P/E Ratio98.88
Dividend YieldN/A
Beta1.15
Surmodics, Inc., together with its subsidiaries, provides medical devices and in vitro diagnostic technologies to the healthcare industry in the United States and internationally. The company operates through two segments, Medical Device and In Vitro Diagnostics. The Medical Device segment designs, develops, and manufactures interventional medical devices primarily for the peripheral vascular market; and offers surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device for the coronary, peripheral, neuro-vascular, urology, and other markets. The Vitro Diagnostics segment provides stabilization products, substrates, antigens, and surface coatings to diagnostics customers; and manufactures or sells components for in vitro diagnostic immunoassay and molecular tests, as well as surface coatings to the diagnostic, biomedical research, and life science markets. Surmodics, Inc. was founded in 1979 and is headquartered in Eden Prairie, Minnesota.

Receive SRDX News and Ratings via Email

Sign-up to receive the latest news and ratings for SRDX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:SRDX
CUSIP86887310
Phone952-500-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$81.34 million
Cash Flow$0.9691 per share
Book Value$8.13 per share

Profitability

Net Income$-4,450,000.00

Miscellaneous

Employees338
Market Cap$653.30 million
OptionableOptionable

SurModics (NASDAQ:SRDX) Frequently Asked Questions

What is SurModics' stock symbol?

SurModics trades on the NASDAQ under the ticker symbol "SRDX."

How were SurModics' earnings last quarter?

SurModics, Inc. (NASDAQ:SRDX) issued its quarterly earnings results on Friday, November, 9th. The company reported $0.05 EPS for the quarter, beating analysts' consensus estimates of ($0.01) by $0.06. The business had revenue of $23.04 million for the quarter, compared to analysts' expectations of $22.54 million. SurModics had a negative net margin of 5.48% and a positive return on equity of 6.12%. View SurModics' Earnings History.

When is SurModics' next earnings date?

SurModics is scheduled to release their next quarterly earnings announcement on Thursday, February 14th 2019. View Earnings Estimates for SurModics.

What guidance has SurModics issued on next quarter's earnings?

SurModics updated its FY 2019 earnings guidance on Friday, November, 9th. The company provided earnings per share guidance of $-0.07-0.23 for the period, compared to the Thomson Reuters consensus estimate of $0.23. The company issued revenue guidance of $92-97 million, compared to the consensus revenue estimate of $90.37 million.

What price target have analysts set for SRDX?

4 Wall Street analysts have issued twelve-month price targets for SurModics' shares. Their predictions range from $74.00 to $90.00. On average, they anticipate SurModics' share price to reach $80.3333 in the next twelve months. This suggests a possible upside of 68.7% from the stock's current price. View Analyst Price Targets for SurModics.

What is the consensus analysts' recommendation for SurModics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SurModics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for SurModics.

What are Wall Street analysts saying about SurModics stock?

Here are some recent quotes from research analysts about SurModics stock:
  • 1. According to Zacks Investment Research, "Surmodics has outperformed the industry in a year’s time. The company continues to gain from its core Medical Device and IVD units and the trend is expected to continue in fiscal 2019 as well. Management is also optimistic about the agreement with MedTech behemoth Abbott for commercialization of its SurVeil drug-coated balloon. Surmodics also expects to complete the TRANSCEND clinical study enrollment by fiscal 2019. Management is hopeful about its new product AVess. On the flip side, a significant year-over-year decline in earnings per share in recent times is worrisome. Surging operating expenses and operating losses at the Medical Device unit are likely to keep the company’s margins under pressure. Surmodics’ drug-coated balloons also face stiff competition in the niche space." (1/14/2019)
  • 2. Needham & Company LLC analysts commented, "SRDX beat consensus F4Q18 revenue and EPS. Management provided FY19 revenue guidance that was above consensus while adjusted EPS guidance was below consensus. Revenue growth slowed to 14.9% in in F3Q18. SRDX’s 3Q18 gross margin was down 120 bps Y/Y and its non-GAAP operating margin was down 1,130 bps Y/Y. Given FY19 revenue guidance that we think is achievable and likely conservative and continued progress with SRDX’s DCB program, we reiterate our Buy rating." (11/9/2018)
  • 3. Barrington Research analysts commented, "We are now modeling adjusted FY/18 adjusted EPS of $(0.02) and revenue of $78.4 million. DCB: Patient enrollment for the company’s TRANSCEND pivotal clinical trial continues and about half of U.S.-based clinical sites have now been activated. As a reminder, the trial to treat peripheral artery disease in the upper leg will be randomized and is expected to include 446 patients at up to 60 clinical sites in the U.S. and 18 sites in Europe. It will feature a head-to-head comparison with a competitor’s already commercialized drug-coated balloon product 510(k) products: Surmodics has now received FDA approvals for its first three 510(k) products (two balloon catheters and a microcatheter). Management remains hopeful that it will enter into partnership for all three products over the next two to four quarters Recommendation: We are maintaining our OUTPERFORM investment rating on SRDX shares. Our new price target is $43, up from our previous $38." (5/3/2018)

Has SurModics been receiving favorable news coverage?

Media coverage about SRDX stock has trended somewhat positive this week, InfoTrie reports. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. SurModics earned a media sentiment score of 0.9 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an impact on the stock's share price in the near term.

Who are some of SurModics' key competitors?

Who are SurModics' key executives?

SurModics' management team includes the folowing people:
  • Mr. Gary R. Maharaj, CEO, Pres & Director (Age 56)
  • Mr. Timothy J. Arens, VP of Corp. Devel. & Strategy, Interim VP of Fin. and CFO (Age 52)
  • Mr. Bryan K. Phillips, Sr. VP of Legal & HR, Gen. Counsel and Corp. Sec. (Age 48)
  • Mr. Thomas A. Greaney, Chief Operating Officer of Medical Devices (Age 53)
  • Mr. Gregg S. Sutton, VP of R&D - Medical Devices (Age 59)

Who are SurModics' major shareholders?

SurModics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Louisiana State Employees Retirement System (0.04%). Company insiders that own SurModics stock include Bryan K Phillips, Charles W Olson, Gary R Maharaj, Gregg S Sutton, Jose H Bedoya, Joseph J Stich, Susan E Knight and Timothy J Arens. View Institutional Ownership Trends for SurModics.

Which institutional investors are selling SurModics stock?

SRDX stock was sold by a variety of institutional investors in the last quarter, including Louisiana State Employees Retirement System. Company insiders that have sold SurModics company stock in the last year include Bryan K Phillips, Charles W Olson, Gary R Maharaj, Gregg S Sutton, Jose H Bedoya, Joseph J Stich, Susan E Knight and Timothy J Arens. View Insider Buying and Selling for SurModics.

How do I buy shares of SurModics?

Shares of SRDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is SurModics' stock price today?

One share of SRDX stock can currently be purchased for approximately $47.62.

How big of a company is SurModics?

SurModics has a market capitalization of $653.30 million and generates $81.34 million in revenue each year. The company earns $-4,450,000.00 in net income (profit) each year or $0.49 on an earnings per share basis. SurModics employs 338 workers across the globe.

What is SurModics' official website?

The official website for SurModics is http://www.surmodics.com.

How can I contact SurModics?

SurModics' mailing address is 9924 WEST 74TH STREET, EDEN PRAIRIE MN, 55344. The company can be reached via phone at 952-500-7000 or via email at [email protected]


MarketBeat Community Rating for SurModics (NASDAQ SRDX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  243 (Vote Outperform)
Underperform Votes:  207 (Vote Underperform)
Total Votes:  450
MarketBeat's community ratings are surveys of what our community members think about SurModics and other stocks. Vote "Outperform" if you believe SRDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel